Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.
Can you give a brief overview of Lonza, the markets you serve and the types of products that you produce? Lonza is a large, multinational corporation serving the entire pharmaceutical product ...
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...
Takeda (TAK) announced topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active ...
Data sources Six databases, six trial registries and prior systematic reviews. Forward and backward citation tracking was employed. Eligibility criteria Randomised controlled trials that compared ...
From 2018 to 2023, the number of concierge and direct primary care practices grew, and there was a substantial shift away from independent ownership. | The number of concierge and direct primary care ...
The number of concierge and direct primary care practices are rapidly rising across the United States, highlighting a ...
Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback